ANDA approval process MCQs With Answer

ANDA Approval Process MCQs With Answer

The Abbreviated New Drug Application (ANDA) pathway underpins timely access to affordable, high-quality generic medicines in the United States. For M. Pharm students specializing in Regulatory Affairs, mastering the technical and regulatory expectations of ANDAs—spanning bioequivalence, CMC, labeling, patent certifications, and GDUFA timelines—is essential. This quiz compiles clinically relevant, exam-oriented MCQs to deepen understanding of Section 505(j), Orange Book strategies, PSGs, biowaivers, RTR/CRL handling, and post-approval change management. Each question is designed to reflect current FDA guidances and operational practices used by industry and reviewers. Use these items to evaluate your readiness for coursework, viva, and real-world dossier planning and troubleshooting in the generic drug development lifecycle.

Q1. What is an ANDA in the context of U.S. FDA approvals?

• Abbreviated New Drug Application submitted under section 505(j) to approve a generic drug
• Original New Drug Application submitted under section 505(b)(1) for innovator products
• 505(b)(2) application relying partly on literature and/or prior findings
• Biologics License Application for therapeutic proteins

Correct Answer: Abbreviated New Drug Application submitted under section 505(j) to approve a generic drug

Q2. The primary objective of an ANDA is to:

• Demonstrate bioequivalence to the RLD and sameness in active ingredient, dosage form, strength, route, and labeling (with permissible differences)
• Establish safety and efficacy with full clinical trials for a new active moiety
• Seek orphan designation for rare diseases
• Obtain marketing authorization under an OTC monograph

Correct Answer: Demonstrate bioequivalence to the RLD and sameness in active ingredient, dosage form, strength, route, and labeling (with permissible differences)

Q3. In the ANDA process, the term “RLD” stands for:

• Regulatory Listed Document
• Reference Listed Drug designated in the Orange Book
• Registered Labeling Dossier
• Reference Licensed Drug

Correct Answer: Reference Listed Drug designated in the Orange Book

Q4. What do Q1 and Q2 sameness indicate for an ANDA product versus the RLD?

• Q1 is quantitative sameness; Q2 is qualitative sameness
• Q1 is qualitative sameness (same excipients); Q2 is quantitative sameness (same excipient amounts within tolerance)
• Q1/Q2 refer to dissolution profile equivalence only
• Q1/Q2 apply only to parenteral products

Correct Answer: Q1 is qualitative sameness (same excipients); Q2 is quantitative sameness (same excipient amounts within tolerance)

Q5. The standard statistical acceptance range for average bioequivalence in a crossover study is:

• 70.00–143.00% for AUC and Cmax (90% CI)
• 80.00–125.00% for AUC and Cmax (90% CI)
• 85.00–115.00% for AUC only (95% CI)
• 75.00–133.00% for Cmax only (90% CI)

Correct Answer: 80.00–125.00% for AUC and Cmax (90% CI)

Q6. Which patent certification in an ANDA claims that the patent is invalid, unenforceable, or will not be infringed?

• Paragraph I certification
• Paragraph II certification
• Paragraph III certification
• Paragraph IV certification

Correct Answer: Paragraph IV certification

Q7. A 30‑month stay of ANDA approval may be triggered when:

• The applicant submits a complete response after a CRL
• The RLD holder sues the ANDA applicant within 45 days of receiving a Paragraph IV notice
• FDA issues a refuse‑to‑receive (RTR) decision
• The ANDA is designated as Competitive Generic Therapy (CGT)

Correct Answer: The RLD holder sues the ANDA applicant within 45 days of receiving a Paragraph IV notice

Q8. 180‑day exclusivity for a generic drug is generally granted to:

• Any ANDA approved on the same day
• The first applicant to file a substantially complete ANDA containing a Paragraph IV certification and meet all approval requirements
• The first applicant to submit controlled correspondence
• Any ANDA with priority review designation

Correct Answer: The first applicant to file a substantially complete ANDA containing a Paragraph IV certification and meet all approval requirements

Q9. FDA Product‑Specific Guidances (PSGs) primarily provide:

• Patent litigation strategies for Paragraph IV cases
• Recommended bioequivalence study designs, analytes, dissolution methods, and Q1/Q2 expectations where relevant
• CMC templates for Module 3
• Billing codes for generic products

Correct Answer: Recommended bioequivalence study designs, analytes, dissolution methods, and Q1/Q2 expectations where relevant

Q10. Which is a recognized pre‑ANDA interaction under GDUFA to clarify development issues?

• Controlled Correspondence to FDA’s Office of Generic Drugs (OGD)
• Type C meeting under PDUFA for biologics
• EU Scientific Advice via EMA
• Pre‑NDA meeting for 505(b)(1)

Correct Answer: Controlled Correspondence to FDA’s Office of Generic Drugs (OGD)

Q11. Which deficiency could result in an FDA Refuse‑to‑Receive (RTR) decision for an ANDA?

• Minor formatting inconsistency in a study report
• Missing required stability data supporting the proposed shelf life
• Optional inclusion of an extra in vitro study
• Presence of a risk management plan for the RLD

Correct Answer: Missing required stability data supporting the proposed shelf life

Q12. Under GDUFA II/III goals, the standard FDA action goal for original ANDAs is generally:

• 6 months from original submission
• 8 months from original submission
• 10 months from original submission
• 24 months from original submission

Correct Answer: 10 months from original submission

Q13. BCS-based biowaivers for immediate-release solid oral dosage forms are typically considered for:

• BCS Class II and IV drugs
• BCS Class I drugs (high solubility, high permeability) and, under certain conditions, Class III drugs
• Only narrow therapeutic index drugs
• All modified-release products

Correct Answer: BCS Class I drugs (high solubility, high permeability) and, under certain conditions, Class III drugs

Q14. An in vivo BE waiver for lower strengths in an ANDA may be granted when:

• The lower strengths have identical colorants
• The product is for pediatric use only
• Q1/Q2 sameness (or acceptable justification), proportional composition, same manufacturing process, and linear PK are demonstrated
• The API is on the WHO prequalified list

Correct Answer: Q1/Q2 sameness (or acceptable justification), proportional composition, same manufacturing process, and linear PK are demonstrated

Q15. Which Drug Master File (DMF) type is typically referenced in an ANDA for the drug substance?

• Type I
• Type II
• Type III
• Type V

Correct Answer: Type II

Q16. Which statement about labeling in an ANDA is TRUE?

• ANDA labeling must be identical to the RLD in all respects with no exceptions
• ANDA labeling should generally match the RLD, with permissible differences such as manufacturer information and carve‑outs for protected uses
• ANDA labeling can freely add new indications not in the RLD
• ANDA labeling is not reviewed by FDA

Correct Answer: ANDA labeling should generally match the RLD, with permissible differences such as manufacturer information and carve‑outs for protected uses

Q17. In the Orange Book, an “AB” therapeutic equivalence code indicates:

• No known or suspected bioequivalence problems
• Therapeutically equivalent products with adequate bioequivalence data supporting substitutability
• Not substitutable
• Products requiring compendial exemption

Correct Answer: Therapeutically equivalent products with adequate bioequivalence data supporting substitutability

Q18. What does an FDA Complete Response Letter (CRL) for an ANDA signify?

• Approval is granted with post‑marketing commitments
• The application is not yet ready for approval; deficiencies must be addressed via an amendment/resubmission
• The ANDA is automatically withdrawn
• Marketing can commence with a risk management plan

Correct Answer: The application is not yet ready for approval; deficiencies must be addressed via an amendment/resubmission

Q19. Which post‑approval change for an ANDA generally requires a Prior Approval Supplement (PAS)?

• Editorial change to the package insert
• Change in container closure color only
• Major change in formulation outside SUPAC limits affecting Q1/Q2 composition
• Annual stability commitment update

Correct Answer: Major change in formulation outside SUPAC limits affecting Q1/Q2 composition

Q20. A Suitability Petition allows submission of an ANDA for:

• A new molecular entity requiring full safety and efficacy studies
• A change in strength, dosage form, or route of administration of a listed drug that does not require clinical investigations for safety/efficacy
• A biologic product under the BLA pathway
• A change introducing a new indication not in the RLD

Correct Answer: A change in strength, dosage form, or route of administration of a listed drug that does not require clinical investigations for safety/efficacy

Download